Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
In the HERO Phase III study (n=930), the oral gonadotropin-releasing hormone antagonist relugolix was associated with superior suppression of testosterone levels to castrate levels through 48 weeks (96.7% v 88.8% with leuprolide; P<0.001 for superiority).
Source:
New England Journal of Medicine
SPS commentary:
A related editorial discusses the results of this study and those of the PROSPER Phase III study of enzalutamide in men with non-metastatic, castration-resistant prostate cancer, also published early online. The authors say that when considered together, these trials raise the question of whether the use of a GnRH antagonist, either oral or subcutaneous, might result in improved cardiovascular outcomes, especially for those at highest risk.